4.3 Review

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations

Journal

EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 11, Issue 5, Pages 575-588

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2015.1032257

Keywords

anakinra; biological agents; canakinumab; macrophage activation syndrome; risk factors; systemic juvenile idiopathic arthritis; tocilizumab

Categories

Ask authors/readers for more resources

Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, arthritis, rash and serositis. Systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that SJIA is an autoinflammatory disorder. IL-1 and IL-6 play a major role in the pathogenesis of SJIA, and treatment with IL-1 and IL-6 inhibitors has shown to be highly effective. However, complications of SJIA, including macrophage activation syndrome, limitations in functional outcome by arthritis and long-term damage from chronic inflammation, continue to be a major issue in SJIA patients' care. Translational research leading to a profound understanding of the cytokine crosstalk in SJIA and the identification of risk factors for SJIA complications will help to improve long-term outcome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available